Effect of Peptide Receptor Radionuclide Therapy (PRRT) with tandem isotopes – [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on qualification [18F]FDG PET/CT in Polish multicenter experience – do we need [18F]FDG | Zendy

Anna Zemczak | Zendy; Maciej Kołodziej | Zendy; Paweł Gut | Zendy; Leszek Królicki | Zendy; Beata KosKudła | Zendy; Grzegorz Kamiński | Zendy; Marek Ruchała | Zendy; Dariusz Pawlak | Zendy; Jolanta Kunikowska | Zendy

Open Access

Effect of Peptide Receptor Radionuclide Therapy (PRRT) with tandem isotopes – [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on qualification [18F]FDG PET/CT in Polish multicenter experience – do we need [18F]FDG

Author(s) -

Anna Zemczak,

Maciej Kołodziej,

Paweł Gut,

Leszek Królicki,

Beata KosKudła,

Grzegorz Kamiński,

Marek Ruchała,

Dariusz Pawlak,

Jolanta Kunikowska

Publication year - 2020

Publication title -

endokrynologia polska

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.413

H-Index - 27

eISSN - 2299-8306

pISSN - 0423-104X

DOI - 10.5603/ep.a2020.0014

Subject(s) - radionuclide therapy , medicine , neuroendocrine tumors , nuclear medicine , progression free survival , peptide receptor , somatostatin receptor , somatostatin , octreotide , overall survival , receptor

Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues is a treatment option for patients with disseminated neuroendocrine tumours (NET). The aim of the study was the evaluation of the role of [¹⁸F]FDG PET/CT in predicting response, progression-free survival (PFS) and overall survival (OS) after tandem therapy [⁹⁰Y]Y/[¹⁷⁷Lu]Lu-DOTATATE.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research